Paradigm Biocapital Advisors LP Tg Therapeutics, Inc. Transaction History

Paradigm Biocapital Advisors LP

  • $2.77 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$6.68 - $18.81 $9.67 Million - $27.2 Million
-1,447,596 Reduced 40.0%
2,171,419 $37.1 Million
Q3 2023

Nov 14, 2023
BUY
$8.36 - $26.5 $30.3 Million - $95.9 Million
3,619,015 New
3,619,015 $30.3 Million
Q3 2022

Nov 14, 2022
SELL
$4.57 - $8.4 $2.1 Million - $3.86 Million
-459,230 Reduced 23.37%
1,505,479 $8.91 Million
Q2 2022

Aug 15, 2022
BUY
$3.74 - $10.66 $7.35 Million - $20.9 Million
1,964,709 New
1,964,709 $8.35 Million

Others Institutions Holding TGTX

# of Institutions
338
Shares Held
88.3M
Call Options Held
2.35M
Put Options Held
1.7M
View Full List

About TG THERAPEUTICS, INC.

TGTX Quotes by TradingView
  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.29B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Paradigm Biocapital Advisors LP Portfolio

Follow Paradigm Biocapital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email